Strasbourg, France & Schiphol, Netherlands, April 2, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs ...
Full-year results and business updateTransgene Continues Progressto Reshape Early-Stage Cancer Treatmentthrough Individualized Neoantigen ...
Transgene has licensed the use of NEC's neoantigen prediction platform to support further development of the cancer vaccine TG4050.
Overcoming efficacy, safety, and manufacturing hurdles through innovative personalized cancer vaccine design ...
Phase I part showed 100% Disease-Free Survival (DFS) after a minimum of 2-year follow-up – providing clinical proof of principle for TG4050 Randomization of all patients expected to be completed by ...
The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a ...
Transgene and NEC Bio ink agreement to prepare the next steps of the development of TG4050 in head and neck cancer: Strasbourg, France Monday, April 6, 2026, 17:00 Hrs [IST] Trans ...
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results